By InvitationNot Applicable

Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study

South Korea800,000 participantsStarted 2026-06-08

Plain-language summary

This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease \[MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)\], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the assessment year.
. Adults aged 19 years or older at the index date (January 1 of each assessment year, annually from 2013 to 2023).
. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the cohort entry year.
. Adults aged 19 years or older at the cohort entry date (i.e., the index date defined per the relevant subgroup cohort in) (per the SAP).
. Meets the operational definition of the index disease or state for one of the four pre-specified subgroup cohorts (MASLD, HF, CKM stage, or High obesity) (per the SAP).

Exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2))

Timeframe: 2013-2018 (Annually)

Proportion of participants with T2D

Timeframe: 2013-2018 (Annually)

Proportion of participants with hypertension

Timeframe: 2013-2018 (Annually)

Proportion of participants with dyslipidemia

Timeframe: 2013-2018 (Annually)

Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation)

Timeframe: 2013-2018 (Annually)

Proportion of participants with CKD

Timeframe: 2013-2018 (Annually)

Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD)

Timeframe: 2013-2018 (Annually)

Trial details

NCT IDNCT07673822

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-08-03

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials

Plain-language summary

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the assessment year.
. Adults aged 19 years or older at the index date (January 1 of each assessment year, annually from 2013 to 2023).
. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the cohort entry year.
. Adults aged 19 years or older at the cohort entry date (i.e., the index date defined per the relevant subgroup cohort in) (per the SAP).
. Meets the operational definition of the index disease or state for one of the four pre-specified subgroup cohorts (MASLD, HF, CKM stage, or High obesity) (per the SAP).

Exclusion criteria

What they're measuring

Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2))

Timeframe: 2013-2018 (Annually)

Proportion of participants with T2D

Timeframe: 2013-2018 (Annually)

Proportion of participants with hypertension

Timeframe: 2013-2018 (Annually)

Proportion of participants with dyslipidemia

Timeframe: 2013-2018 (Annually)

Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation)

Timeframe: 2013-2018 (Annually)

Proportion of participants with CKD

Timeframe: 2013-2018 (Annually)

Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD)

Timeframe: 2013-2018 (Annually)